Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.
J Cyst Fibros. 2023 Mar;22 Suppl 1(Suppl 1):S39-S44. doi: 10.1016/j.jcf.2022.12.016. Epub 2023 Jan 17.
J Cyst Fibros. 2023.
PMID: 36658041
Free PMC article.
Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, t …
Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective C …
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A.
Benhorin J, et al. Among authors: kerem b.
Circulation. 2000 Apr 11;101(14):1698-706. doi: 10.1161/01.cir.101.14.1698.
Circulation. 2000.
PMID: 10758053
Flecainide also normalized the marked baseline repolarization dispersion in most mutation carriers. These effects among carriers were maintained during long-term (9 to 17 months) outpatient flecainide therapy with no adverse effects. ...
Flecainide also normalized the marked baseline repolarization dispersion in most mutation carriers. These effects among carriers were mainta …
Item in Clipboard
Cite
Cite